J&J Forecasts March Approval For Its Single-Dose Vaccine
While Johnson & Johnson expects to release trial results in the next two weeks, the vaccine maker also says that it is behind in its promised production schedule.
The independent source for health policy research, polling, and news.
17,181-17,200 of 112,997 results
While Johnson & Johnson expects to release trial results in the next two weeks, the vaccine maker also says that it is behind in its promised production schedule.
The retailer will offer its workers four hours of pay. The Washington Post reports on steps other companies may take to encourage vaccinations.
Millions of vaccine doses sit on shelves at many U.S. hospitals that are overwhelmed by the escalating covid crisis, Roll Call reports.
The virus hijacks the lungs immune cells and uses them to spread across the lungs, according to research published in Nature. Scientists plan trials to dampen the inflammatory response of the cells. Research news is on immunity and a post-covid world.
Vaccination campaigns, renewed commitments to masks and physical distancing and increased funding for pandemic response efforts form the backbone of the plan President-elect Joe Biden will detail Thursday.
A new study from the Centers for Disease Control and Prevention found that in-person classes at K-12 schools didn't appear to lead to spikes in covid cases compared to online-only learning. The study also found that transmission rates by age group increased as the school level increased.
Scientists fear that the progression of coronavirus mutations is only beginning to take hold and outbreaks will surge even further in the coming months, particularly in the U.S.
Like other global mutations, the two variants that likely originated in the U.S. are more contagious than the SARS-CoV-2 coronavirus. One of those strains, discovered by Ohio State University researchers, has become the dominant spreader in the Columbus, Ohio area.
Vaccine makers Pfizer and Moderna hope that 70% of Americans can be inoculated by July. The immediate future looks far more dire though, with the rate of covid deaths continuing to increase and looking to get worse.
Today's early morning highlights from the major news organizations.
Editorial pages express views about these pandemic topics and other public health issues.
Opinion writers weigh in on best ways to increase vaccine supply and get it to the most vulnerable.
Read recent commentaries about drug-cost issues.
Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN's Prescription Drug Watch roundup.
Verve Therapeutics says its one-time treatment significantly reduced LDL cholesterol for six months. The company hopes to begin clinical trials next year on people born with HeFH, a genetic heart disease that causes lifelong, high LDL levels. Other news is on Intarcia Therapeutics and AI tools.
Ireland's prime minister responded to the report by saying "We did this to ourselves, we treated women exceptionally badly." News is on covid developments, as well.
The ability to know test results in 15 minutes would allow offices, theaters and restaurants to reopen sooner.
The charges against Republican Rick Snyder and former health director Nick Lyon — who previously faced involuntary manslaughter charges that were eventually dropped — haven't been announced. The Flint water scandal contaminated the African American-majority city's drinking water with lead.
The American Cancer Society traces the progress to a reduction in smoking and advances in lung cancer treatment.
Late-stage testing in Brazil shows the covid-19 vaccine developed by Sinovac Biotech to be 50.38% effective overall, in contrast with the 78% announced last week. Researchers acknowledge the earlier number only included volunteers mildly sick.
© 2026 KFF